ANN ARBOR, Mich., July 8 /PRNewswire/ -- NanoBio(R) Corp., a biopharmaceutical company focused on developing and commercializing novel products to prevent and treat infectious diseases, today announced the appointment of Daniel B. Dubin, M.D., to its board of directors.
Dr. Dubin currently serves as Vice Chairman and a Director at Leerink Swann, a leading healthcare and biotechnology investment banking firm.
“Dan’s keen understanding of the life sciences investment banking field and his clinical experience as a dermatologist bring a dual perspective that will help us create value and distinction as an emerging company in the biotechnology sector,” said James R. Baker Jr., founder and Chairman of NanoBio. “His expertise and informed perspective in the field of dermatology will greatly enhance the strategic positioning of our topical treatments for herpes labialis, onychomycosis and other dermatologic infections.”
A Harvard-trained dermatologist, Dr. Dubin served as Ambulatory Medical Director of the dermatology practice at Brigham and Women’s Hospital. In 1996, Dr. Dubin co-founded MEDACorp to provide life science companies and institutional investors with expert insight into the development and adoption of biopharmaceuticals, medical devices and diagnostics. When MEDACorp merged with Leerink Swann in 2001, Dr. Dubin became a Director at Leerink Swann and later assumed the position of Vice Chairman. Dr. Dubin also serves on the board of Eleme Medical, a cellulite treatment company.
NanoBio’s lead products are topical lotions and mucosal vaccines to combat a wide array of viruses, bacteria and fungi. The company’s nanoemulsion-based products have demonstrated potent antimicrobial effects in several phase 1 and 2 clinical trials without safety concerns or systemic absorption. The products use a physical mode of action rather than chemical synthesis to disrupt pathogen membranes, rendering the emergence of drug resistance unlikely.
About NanoBio
NanoBio(R) Corp. is a privately held biopharmaceutical company focused on developing and commercializing anti-infective products and mucosal vaccines derived from its patented NanoStat(TM) technology platform. The company’s lead product candidates are treatments for herpes labialis (cold sores), onychomycosis (nail fungus), MRSA and mucosal vaccines for influenza and hepatitis B. The company’s headquarters and laboratory facilities are located in Ann Arbor, Mich.
CONTACT: John Coffey, Vice President, Business Development of NanoBio
Corporation, +1-734-302-9107, john.coffey@nanobio.com
